March 19, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Pricing of Public Offering of 4,500,000 Shares of Common Stock

SEATTLE, March 19, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $23.00 per share pursuant to its shelf registration statement. NanoString will sell 2,500,000 shares of common... Read more

March 18, 2019 Clinical Research/Diagn. Life Science Tools PR/Corporate

NanoString Technologies Announces Commencement of Public Offering of Common Stock

SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced an underwritten public offering of 4,500,000 shares of its common stock pursuant to its shelf registration statement. NanoString intends to offer and sell, subject to market and other conditions, 2,500,000 shares of common stock, and Clarus... Read more

March 18, 2019 Bio/Pharma/CRO Clinical Research/Diagn. Environ, Ag./Food & Bev Informatics & Software Lab Top-10 Mass Spectrometry Molecular Spectroscopy Product Launch

Bruker Highlights New Systems and Applied Market Solutions at Pittcon

PHILADELPHIA, March 18, 2019 /PRNewswire/ — At Pittcon 2019, Bruker (Nasdaq: BRKR) this week highlights new and innovative analytical systems and high-value applied market solutions for food analysis, pharma applications, materials science research and quality control, clinical and preclinical research, and advances in scientific software solutions. Frank H. Laukien, Ph.D., Bruker’s President and CEO, commented:  “Our... Read more

March 14, 2019 Bio/Pharma/CRO Clinical Research/Diagn. Product Launch

Lonza Expands Mycoplasma Detection Portfolio with New Luminometer Designed to Accelerate and Simplify Testing

Walkersville, MD (USA) / Basel, Switzerland, 14 March 2019 – Lonza has further strengthened its extensive mycoplasma detection portfolio with the addition of the Lucetta™ 2 Luminometer, a single-tube system designed to simplify and accelerate mycoplasma detection in cell cultures. Pharmaceutical, biotechnology and academic researchers can now rely on this compact, portable and easy-to-use instrument to... Read more

March 14, 2019 Clinical Research/Diagn. Lab Top-10 M&A, Partnerships

Merck KGaA, Darmstadt, Germany, Announces Collaboration with Iktos for Generative Artificial Intelligence (AI) Technology

Darmstadt, Germany, March 14, 2019 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. “This agreement is another illustration of... Read more

March 12, 2019 Clinical Research/Diagn. M&A, Partnerships

The Netherlands Cancer Institute (NKI) selects Labguru to further pioneering cancer research and treatment

NKI completes institute wide adoption of Labguru to increase efficiency and maximize productivity in the laboratory 12 March 2019, Cambridge, MA: BioData has announced The Netherlands Cancer Institute (NKI) has started an institute wide deployment of its flagship product Labguru. NKI has secured an institutional licence of Labguru’s Electronic Lab Notebook (ELN) for further collaboration across... Read more

March 12, 2019 Clinical Research/Diagn. M&A, Partnerships

Crown Bioscience Inc. and Charles River Laboratories Enter Agreement to Expand Access to ZDSD Rat Model

San Diego, Calif. and Wilmington, Mass. – March 12, 2019 – Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research today announced a licensing agreement with Charles River Laboratories International, Inc.’s Research Models and Services business. The agreement, designed to expand access to... Read more

March 11, 2019 Clinical Research/Diagn. Informatics & Software Life Science Tools Product Launch

DNAnexus Introduces Innovative Clinico-Genomic Browser to Allow Diverse Research Teams to Explore Complex Human Data Sets

The Regeneron Genetics Center successfully deployed the cohort browser against a large genomic and phenotypic UK Biobank data set March 11, 2019 09:15 AM Eastern Daylight Time MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–DNAnexus, Inc., the leader in biomedical informatics and data management, today announced the addition of an innovative browser for clinico-genomic cohorts to its DNAnexus Apollo™... Read more

March 11, 2019 Clinical Research/Diagn.

Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane

Basel, 11 March 2019 Roche’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane PD-L1 (SP142) was the enrollment assay used in the IMpassion130 trial, the first positive phase III immunotherapy regimen study in triple-negative breast cancer Each year about... Read more

March 7, 2019 Clinical Research/Diagn. Life Science Tools

Novel enzyme from LGC, Biosearch Technologies is fast and specific, even at room temperature

LGC, Biosearch Technologies proudly introduces RapiDxFire™ Thermostable RT, a truly thermostable reverse transcriptase (RT) designed specifically to meet the needs of diagnostic kit developers.   This reverse transcriptase has a temperature optimum from 55 – 80 °C, improving reaction specificity and allowing synthesis from diverse RNA templates.  It is also fast, with a reaction time of five... Read more